A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, November 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#36 of 2,501)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

policy: 1 policy source

patent: 8 patents

Citations

dimensions_citation: 82 Dimensions

Readers on

mendeley: 90 Mendeley

Summary Policy documents Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Lenvima for Renal Cell Carcinoma – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 08 Aug 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.